Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Harmony Biosciences Holdings (HRMY)

Harmony Biosciences names Adam Zaeske chief commercial officer, replacing Jeffrey Dierks

Neutral Impact 3 of 5 leadership Written later

Harmony Biosciences said Chief Commercial Officer Jeffrey Dierks is leaving for personal reasons, effective March 31, 2025, and named Adam Zaeske, formerly a senior executive at Takeda Pharmaceuticals, as his successor on the same date. Dierks's separation agreement provides a $476,215 lump-sum payment and accelerated vesting of part of his equity awards. The company's CEO said the company remains confident in its 2025 revenue guidance.

Key points

  • Jeffrey Dierks departs as Chief Commercial Officer effective March 31, 2025, for personal reasons
  • Separation agreement dated March 20, 2025 provides a $476,215 lump-sum payment and accelerated vesting of awards for the portion that would have vested in calendar 2025
  • Adam Zaeske becomes Executive Vice President and Chief Commercial Officer effective March 31, 2025; he previously served as Senior Vice President at Takeda Pharmaceuticals from April 2022 to March 2025
  • CEO Jeffrey Dayno said the company remains confident in its 2025 revenue guidance

The filing

CompanyHarmony Biosciences Holdings (HRMY)
Form8-K, current report
Filed with the SECMar 24, 2025, 8:15 AM ET
Accession number0001558370-25-003502

Items reported: 5.02 Director / Officer Change8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 24, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.